As of May 25
| -0.04 / -1.00%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 30.00 and a low estimate of 19.50. The median estimate represents a +406.33% increase from the last price of 3.95.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.